The ATP13A2 Knockout A-549 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population for studying ATP13A2 function. This loss-of-function model is generated by targeted gene disruption in A-549 cells, yielding a heterogeneous pool that reliably captures ATP13A2-dependent phenotypes without clonal selection artifacts commonly associated with monoclonal lines.
The host A-549 cell line originates from a lung adenocarcinoma of a 58-year-old Caucasian male and harbors a KRAS G12S mutation, serving as a paradigm of type II alveolar epithelium. These adherent epithelial cells retain robust lysosomal and autophagic activity, offering a physiologically relevant background for investigating lysosomal ATPases and endolysosomal pathways in a genetically defined cancer context.
ATP13A2 encodes a lysosomal P5-type ATPase that transports polyamines and cations, sustaining lysosomal acidification and proteolytic function. Transcriptionally regulated by TFEB and responsive to PGC1??, NRF2, and HIF1??, ATP13A2 promotes cathepsin B/D activation, facilitates LC3?II and SQSTM1/p62 turnover, and supports mitochondrial integrity via the PINK1?PRKN pathway. ATP13A2 interacts with SNCA, HDAC6, HSPA8, and PRKN to prevent ???synuclein aggregation and coordinates Nrf2?target gene expression, thus linking lysosomal health to proteostasis and redox homeostasis.
ATP13A2 knockout in A-549 cells disrupts lysosomal cation homeostasis, leading to alkalinization, impaired autophagic flux, ???synuclein accumulation, mitochondrial depolarization, and heightened oxidative stress. These features mirror Parkinson??s disease pathology, and the KRAS-mutant background may accentuate lysosomal stress, enabling dissection of oncogenic crosstalk with autophagy. The model thus permits investigation of ATP13A2-dependent mechanisms in a tractable epithelial system relevant to both neurodegenerative and cancer biology.
Researchers can employ these cells for Western blotting and RT?qPCR analysis of LAMP1, CTSD, LC3?II, and SQSTM1/p62; immunofluorescence of LC3 puncta and LAMP1 vesicles; JC?1 flow cytometry for mitochondrial membrane potential; cathepsin activity assays; and ???synuclein aggregation measurements. Autophagy flux assays with bafilomycin A1, ROS quantification, and viability tests under oxidative stress further characterize the knockout phenotype. This polyclonal knockout pool is an ideal platform for drug screening targeting lysosomal dysfunction and mitochondrial quality control. For additional information, contact Ascent Research.
